Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Scalp Psoriasis
Interventions: 0.045% Tazarotene/0.01% Halobetasol Lotion; Drug
Lead sponsor: Dermatology Consulting Services, PLLC; Network
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Psoriasis
Interventions: Clobetasol propionate foam, Vehicle foam; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 12 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Fremont, California • Louisville, Kentucky

Conditions: Pregnancy
Interventions: Amevive exposure; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Psoriasis
Interventions: Enstilar, Deucravacitinib; Drug
Lead sponsor: Psoriasis Treatment Center of Central New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Psoriasis Vulgaris
Interventions: Polysomnography (PSG); Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Psoriasis
Interventions: Etanercept, Placebo injections; Biological · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Irvine, California • Winston-Salem, North Carolina • Seattle, Washington

Conditions: Moderate to Severe Plaque-type Psoriasis
Interventions: AIN457 150mg, AIN457 300mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 967 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 33
States / cities: Fresno, California • Pasadena, California • Sacramento, California + 28 more

Conditions: Psoriasis, Stress
Interventions: Transdermal Electrical Neuromodulator (TEN); Device
Lead sponsor: Thync Global, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Fremont, California • San Diego, California • Santa Monica, California

Conditions: Plaque Psoriasis
Interventions: Duobrii 0.01 % / 0.045 % Topical Lotion, CeraVe, Topical Cream; Drug
Lead sponsor: Austin Institute for Clinical Research; Network
Eligibility: 18 Years to 99 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Houston, Texas • Pflugerville, Texas

Conditions: Psoriasis, Atopic Dermatitis
Interventions: Pandel Cream 0.1%; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 3 Months and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 3
States / cities: Omaha, Nebraska • Hilton Head Island, South Carolina • Nashville, Tennessee

Conditions: Psoriatic Arthritis
Interventions: Secukinumab (75 mg), Secukinumab (150 mg), Placebo Comparator; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 25
States / cities: Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 20 more

Conditions: Plaque Psoriasis
Interventions: Tazarotene Cream 0.05%, TAZORAC® (tazarotene) Cream 0.05%, Placebo; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 855 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 30
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 25 more

Conditions: Dermatitis, Psoriasis
Interventions: Narrowband Ultraviolet B (TL-01UVB) Therapy, Topical Psoralen plus ultraviolet A (PUVA); Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Psoriasis
Interventions: LD-Aminopterin oral capsule, Placebo oral capsule; Drug
Lead sponsor: Syntrix Biosystems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Scottsdale, Arizona • Seattle, Washington • Spokane, Washington

Conditions: Plaque Psoriasis
Interventions: clobetasol propionate spray, clobetasol propionate ointment; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Fremont, California • Vallejo, California • Detroit, Michigan + 3 more

Conditions: Plaque Psoriasis
Interventions: IDP-122 Lotion, IDP-122 Vehicle Lotion; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 15
States / cities: Hot Springs, Arkansas • Encinitas, California • Encino, California + 12 more

Conditions: Plaque Psoriasis
Interventions: DFD-01 (betamethasone dipropionate) Spray, 0.05%; Drug
Lead sponsor: Primus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Arlington Heights, Illinois • New Albany, Indiana • Louisville, Kentucky + 1 more

Conditions: Psoriasis, Pain
Interventions: Heating Pack, Ice pack; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: Not listed
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Arthritis, Psoriatic
Interventions: Guselkumab, Golimumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Phoenix, Arizona • Searcy, Arkansas • Avon Park, Florida + 16 more

Conditions: Psoriasis
Interventions: Occlusive dressing; Device
Lead sponsor: Teikoku Pharma USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Organ Transplant Rejection, Psoriasis
Interventions: Sustained Release Injectable Tacrolimus; Drug
Lead sponsor: Auritec Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Atopic Dermatitis, Psoriasis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: San Diego, California • Denver, Colorado

Conditions: Plaque Psoriasis
Interventions: MEDI-507, Placebo; Drug · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 36
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 29 more

Conditions: Parapsoriasis, Healthy Volunteers
Interventions: CC-90005, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis

Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam

AMEVIVE® Pregnancy Registry

Combination of Sotyktu and Enstilar for Plaque Psoriasis

Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

12-Week Study Assessing Change in Psoriasis Severity and Level of Stress Using TEN

Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults

Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

Study to Compare Different Light Therapies (Narrowband Ultraviolet B vs PUVA) for Hand and Foot Skin Diseases.

Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis

Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis

Reduction of Pain Caused by Biologic Drugs in Psoriasis

A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

Study of a New Dressing for Use With Topical Medications

Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study

Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis

A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis

Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis